Alnylam Pharmaceuticals (STU:DUL) Research & Development : €956 Mil (TTM As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Alnylam Pharmaceuticals Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Alnylam Pharmaceuticals's Research & Development for the three months ended in Mar. 2024 was €240 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €956 Mil.

Alnylam Pharmaceuticals Research & Development Historical Data

The historical data trend for Alnylam Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Research & Development Chart

Alnylam Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Research & Development

Get a 7-Day Free Trial

589.60

538.26

701.06

833.57

921.05

Alnylam Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Research & Development	Get a 7-Day Free Trial															215.35	229.39	237.23	249.55	240.12

Alnylam Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €956 Mil.

Alnylam Pharmaceuticals (STU:DUL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Alnylam Pharmaceuticals Research & Development Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Alnylam Pharmaceuticals (STU:DUL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (STU:DUL) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

ALNY:USA ALNY:Mexico DUL:Germany

Address

675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142

Website

https://www.alnylam.com

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals (STU:DUL) Headlines

No Headlines